CellularNanoMachines: Development of Stimuli Responsive Nanoparticle carrying T lymphocytes in the Fight against Cancer
Sloan-Kettering Institute for Cancer Research CORPORATION
participó en un
H2020
H2020-MSCA-IF-2017
The cancer burden represents an overarching health problem and it is essential that EU institutions develop the next generation of diagnosti...
2018-03-07 - 2022-01-03 | Financiado
2018-03-07 - 2022-01-03 | Financiado
LungCARD: Blood test for clinical therapy guidance of non small cell lung cancer patients
Sloan-Kettering Institute for Cancer Research CORPORATION
participó en un
H2020
H2020-MSCA-RISE-2016
Lung cancer is the most common cancer worldwide. NSCLC alone make up about 75% of all lung cancers and most hospitals currently test all NSC...
2016-12-02 - 2022-10-31 | Financiado
2016-12-02 - 2022-10-31 | Financiado
THYMISTEM: Development of Stem Cell Based Therapy for Thymic Regeneration
Sloan-Kettering Institute for Cancer Research CORPORATION
participó en un
FP7
Reconstitution of immune system function in immunocompromised patients depends on the presence of a functional thymus, and specifically, on...
Financiado
Financiado
NEUROSTEMCELL: European Consortium for Stem Cell Therapy for Neurodegenerative Diseases
Sloan-Kettering Institute for Cancer Research CORPORATION
participó en un
FP7
The NEuroStemCell consortium will foster collaboration between leading European experimental and clinical researchers in order to maximise t...
Financiado
Financiado
MLPM2012: Machine Learning for Personalized Medicine
Sloan-Kettering Institute for Cancer Research CORPORATION
participó en un
FP7
"Over the last decade, enormous progress has been made on recording the health state of an individual patient down to the molecular level of...
Financiado
Financiado
* No se disponen de datos de la empresa actual.